Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.

Abstract

The incidence of esophagogastric cancer is rapidly rising, but only a minority of patients derive durable benefit from current therapies. Chemotherapy as well as anti-HER2 and PD-1 antibodies are standard treatments. To identify predictive biomarkers of drug sensitivity and mechanisms of resistance, we implemented prospective tumor sequencing of patients… (More)
DOI: 10.1158/2159-8290.CD-17-0787

Topics

Cite this paper

@article{Janjigian2018GeneticPO, title={Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.}, author={Yelena Yuriy Janjigian and Francisco S{\'a}nchez-Vega and Philip Jonsson and Walid K Chatila and Jaclyn Frances Hechtman and Geoffrey Yuyat Ku and Jamie C Riches and Yaelle Tuvy and Ritika Kundra and Nancy Bouvier and Efsevia Vakiani and Jianjiong Gao and Zachary J Heins and Benjamin E. Gross and David Paul Kelsen and Liying Zhang and Vivian E Mack Strong and Mark A. Schattner and Hans Hermann Gerdes and Daniel G. Coit and Manjit Bains and Zsofia Kinga Stadler and Valerie W. Rusch and David R. Jones and Daniela Molena and Jinru Shia and Mark E. Robson and Marinela Capanu and Sumit Middha and Ahmet Zehir and David M. Hyman and Maurizio Scaltriti and Marc Ladanyi and Neal Rosen and David H. Ilson and Michael F. Berger and Laura A Tang and Barry S. Taylor and David B. Solit and Nikolaus Schultz}, journal={Cancer discovery}, year={2018}, volume={8 1}, pages={49-58} }